Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 11/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | ALPI | P09923 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | XIAP | P98170 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610098 | 1.00 | TPH1 (0.61) | TPH1SLC7A5DPP4ALPIPKM | |
| SCHEMBL30722996 | 1.00 | TPH1 (0.61) | TPH1SLC7A5DPP4ALPIPKM | |
| Dl-Phenylalanine SCHEMBL27778634 | 0.89 | SLC7A5 (0.71) | TPH1SLC7A5DPP4ALPIPKM | |
| SCHEMBL26158250 | 0.89 | SLC7A5 (0.54) | TPH1SLC7A5DPP4ALPIPKM | |
| Tyrosine SCHEMBL27973453 | 0.86 | SLC7A5 (0.67) | TPH1SLC7A5DPP4ALPIPKM | |
| Dl-Phenylalanine SCHEMBL28506940 | 0.84 | SLC7A5 (0.63) | TPH1SLC7A5DPP4ALPIPKM | |
| SCHEMBL31295364 | 0.84 | SLC7A5 (0.54) | TPH1SLC7A5DPP4ALPIPKM | |
| SCHEMBL30673627 | 0.84 | SLC7A5 (0.54) | TPH1SLC7A5DPP4ALPIPKM | |
| SCHEMBL12273163 | 0.84 | SLC7A5 (0.54) | TPH1SLC7A5DPP4ALPIPKM | |
| SCHEMBL29462215 | 0.84 | SLC7A5 (0.54) | TPH1SLC7A5DPP4ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PEPTIDREAM INC. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4541805-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PeptiDream Inc. (JP) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025070731-A1 | PEPTIDEPEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025070720-A1 | PEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2023243120-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | ペプチドリーム株式会社 | 2023-12-21 | — | — | WO | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-6448408-B1 | CHEMICAL INTERMEDIATES IN PREPARATION OF N-MERCAPTOACYL DERIVATIVE OF PHENYLALANINE WITH PHARMALOGICAL ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2002-09-10 | — | — | US | disclosed |
| US-20020028946-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON GROUP S.P.A. (IT) | 2002-03-07 | — | — | US | disclosed |
| EP-0948492-B1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON SPA (IT) | 2001-07-11 | — | — | EP | disclosed |
| EP-0948492-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON GROUP S.p.A. (IT) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998028284-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | ZAMBON GROUP S.P.A. (IT) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | BMP4, BMP1, BMPR2 | TPH1 4441/4885SLC7A5 2541/4885DPP4 945/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | TPH1 3227/4885SLC7A5 21/4885DPP4 107/4885 |
| US-20020028946-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES | PAH, TYR, CYP2S1 | TPH1 61/4885SLC7A5 51/4885DPP4 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.